13 research outputs found
Evaluation of In-Hospital Management of Pneumonia Patients
Background: To audit the practices involved in the management of pneumonia patients in our settings and to compare them with standard recommended guidelines by the British Thoracic Society (BTS).
Methods: In this cross-sectional study inclusion criteria were all patients admitted with suspicion of lower respiratory infection/pneumonia, with no exclusion. Clinical presentation, diagnostic workup, treatment modalities and complications were analyzed.Results: Majority (97.3%) of the patients were admitted through an emergency. Length of stay was less than 1 week in 72%. CURB-65 was applied in 2.6%. Majority (96% ) patients had inadequate investigations. Most commonly prescribed the first-line antibiotic was Cephalosporins given to 56%.. Co-morbidities were registered in 96%, which contributed towards expiry rate of 60%.Conclusion: The management of pneumonia patients in our settings is not in line with the recommended standard guidelines. This results in increased complications, prolonged hospital stay, and an overall poor prognosis
Real Time Monitoring of Environmental Parameters (RT-MEP)
The fluctuations in parameter pertaining to environment such as temperature, soil movement, light intensity etc. can directly or indirectly influence mankind and their activities. This paper focuses on designing a new workbench that takes into account hardware as well as software aspects in monitoring and assessment of environmental anomalies. The idea is aimed to create an advanced, low cost and user friendly interface. Realization is being done by the orientation and placement of contemporary selection of sensors aimed to record and alert any perturbations in parameters such as soil moisture, atmospheric pressure, temperature, light intensity and soil movement. Sensed data is then transferred and stored continuously in real time at base station. Any unusual change in environment and disaster can be observed via abnormal values of the parameters. This work focuses to provide an inexpensive yet real time monitoring approach for agrarian purposes as well as alert for catastrophic situations
Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event Risk.
OBJECTIVES: Guidelines recommend to initiate anticoagulation within 4-14 days after cardioembolic stroke. Data supporting this did not account for key factors potentially affecting the decision to initiate anticoagulation such as infarct size, hemorrhagic transformation, or high risk features on echocardiography. METHODS: We pooled data from stroke registries of 8 comprehensive stroke centers across the United States. We included consecutive patients admitted with ischemic stroke and atrial fibrillation. The primary predictor was timing of initiating anticoagulation (0-3 days, 4-14 days, or >14 days) and outcomes were recurrent stroke/TIA/systemic embolism, symptomatic intracerebral hemorrhage (sICH), and major extracranial hemorrhage (ECH) within 90 days. RESULTS: Among 2084 patients, 1289 met the inclusion criteria. The combined endpoint occurred in 10.1% (n = 130) subjects (87 ischemic events, 20 sICH, and 29 ECH). Overall, there was no significant difference in the composite endpoint between the three groups: 0-3 days [10.3% (64/617)], 4-14 days [(9.7%) 52/535)], >14 days [10.2% (14/137), p=0.933]. In adjusted models, patients started on anticoagulation between 4-14 days did not have a lower rate of sICH (vs. 0-3 days) (OR 1.49 95% CI 0.50 â 4.43) neither did they have a lower rate of recurrent ischemic events (vs. > 14 days) (OR 0.76 95% CI 0.36 â 1.62, p = 0.482). INTERPRETATION: In this multicenter real world cohort, the recommended (4-14 days) time frame to start oral anticoagulation was not associated with reduced ischemic and hemorrhagic outcomes. Randomized trials are required to determine the optimal timing of anticoagulation initiation
Early ischaemic and haemorrhagic complications after atrial fibrillation-related ischaemic stroke: analysis of the IAC study.
INTRODUCTION: Predictors of long-term ischemic and hemorrhagic complications in atrial fibrillation (AF) have been studied, but there is limited data on predictors of early ischemic and hemorrhagic complications after AF associated ischemic stroke. We sought to determine these predictors. METHODS: The Initiation of Anticoagulation after Cardioembolic stroke (IAC) study is a multicenter retrospective study across that pooled data from consecutive patients with ischemic stroke in the setting of AF from stroke registries across 8 comprehensive stroke centers in the United States. The co-primary outcomes were recurrent ischemic event (stroke/TIA/systemic arterial embolism) and delayed symptomatic intracranial hemorrhage (d-sICH) within 90 days. We performed univariate analyses and cox regression analyses including important predictors on univariate analyses to determine independent predictors of early ischemic events (stroke/TIA/systemic embolism) and d-sICH. RESULTS: Out of 2084 patients, 1520 patients qualified; 104 patients (6.8%) had recurrent ischemic events and 23 patients (1.5%) had d-sICH within 90 days from the index event. In cox-regression models, factors associated with a trend for recurrent ischemic events were prior stroke or TIA (HR 1.42, 0.96 â 2.10) and ipsilateral arterial stenosis with 50â99% narrowing (HR 1.54, 0.98 â 2.43). Those associated with sICH were female sex (HR 2.68, 1.06â 6.83), history of hyperlipidemia (HR 2.91, 1.08 â 7.84), and early hemorrhagic transformation (HR 5.35, 2.22 â 12.92). CONCLUSION: In patients with ischemic stroke and AF, predictors of d-sICH are different than those of recurrent ischemic events therefore recognizing these predictors may help inform early stroke versus d-sICH prevention strategies
Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study.
BACKGROUND AND PURPOSE: In patients with acute ischemic stroke and atrial fibrillation (AF), treatment with low molecular weight heparin (LMWH) increases early hemorrhagic risk without reducing early recurrence and there is limited data comparing warfarin to direct oral anticoagulant (DOAC) therapy. We aim to compare the effects of the treatments above on the risk of 90-day recurrent ischemic events and delayed symptomatic intracranial hemorrhage (d-sICH). METHODS: We included consecutive patients with acute ischemic stroke and AF from the Initiation of Anticoagulation after Cardioembolic stroke (IAC) study pooling data from stroke registries of 8 comprehensive stroke centers across the United States. We compared recurrent ischemic events and d-sICH between each of the following groups in separate cox-regression analyses: 1) DOAC versus warfarin and 2) Bridging with heparin/LMWH versus no bridging, adjusting for pertinent confounders to test these associations. RESULTS: We identified 1,289 patients who met the âbridging versus no bridgingâ analysis inclusion criteria and 1,251 patients who met the âDOAC versus warfarinâ analysis inclusion criteria. In adjusted cox-regression models, bridging (versus no bridging) treatment was associated with a high risk of d-sICH (HR 2.74 95% CI 1.01 â 7.42) but a similar rate of recurrent ischemic events (HR 1.23 95% CI 0.63 â 2.40). Furthermore, DOAC (versus warfarin) treatment was associated with a lower risk of recurrent ischemic events (HR 0.51 95% CI 0.29 â 0.87) but not d-sICH (HR 0.57 95% CI 0.22 â 1.48). CONCLUSION: Our study suggests that patients with ischemic stroke and AF would benefit from the initiation of a DOAC without bridging therapy. Due to our study limitations, these findings should be interpreted with caution pending confirmation from large prospective studies
Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation.
BACKGROUND AND PURPOSE: Understanding factors associated with ischemic stroke despite therapeutic anticoagulation is an important goal to improve stroke prevention strategies in patients with atrial fibrillation (AF). We aim to determine factors associated with therapeutic or supratherapeutic anticoagulation status at the time of ischemic stroke in patients with AF. METHODS: The Initiation of Anticoagulation after Cardioembolic stroke (IAC) study is a multicenter study pooling data from stroke registries of eight comprehensive stroke centers across the United States. Consecutive patients hospitalized with acute ischemic stroke in the setting of AF were included in the IAC cohort. For this study, we only included patients who reported taking warfarin at the time of the ischemic stroke. Patients not on anticoagulation and patients who reported use of a direct oral anticoagulant were excluded. Analyses were stratified based on therapeutic (INR â„2) versus subtherapeutic (INR <2) anticoagulation status. We used binary logistic regression models to determine factors independently associated with anticoagulation status after adjustment for pertinent confounders. In particular, we sought to determine whether atherosclerosis with 50% or more luminal narrowing in an artery supplying the infarct (a marker for a competing atherosclerotic mechanism) and small stroke size (†10 mL; implying a competing small vessel disease mechanism) related to anticoagulant status. RESULTS: Of the 2084 patients enrolled in the IAC study, 382 patients met the inclusion criteria. The mean age was 77.4 ± 10.9 years and 52.4% (200/382) were men. A total of 222 (58.1%) subjects presented with subtherapeutic INR. In adjusted models, small stroke size (OR 1.74 95% CI 1.10 â 2.76, p = 0.019) and atherosclerosis with 50% or more narrowing in an artery supplying the infarct (OR 1.96 95% CI 1.06 â 3.63, p = 0.031) were independently associated with INR â„2 at the time of their index stroke. CONCLUSION: Small stroke size (†10 ml) and ipsilateral atherosclerosis with 50% or more narrowing may indicate a competing stroke mechanism. There may be important opportunities to improve stroke prevention strategies for patients with AF by targeting additional ischemic stroke mechanisms to improve patient outcomes